Follow us on:

Linkedin Facebook

GSK reaches confidential settlement with James Goetz in Zantac litigation

GSK

GSK plc (LON/NYSE: GSK) today confirmed it has reached a confidential settlement with James Goetz, and the case he filed in California state court, set to begin trial on July 24, 2023, will be dismissed.

The settlement reflects the Company’s desire to avoid distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

Share on:

Latest Company News

GSK

GSK subsidiary TESARO starts legal action over Jemperli licence dispute

TESARO, part of GSK, has filed a case in the Delaware Chancery Court claiming AnaptysBio has breached its licence agreement for the cancer treatment Jemperli.
GSK Plc

GSK Plc lifts 2025 guidance after strong Q3 sales and profit growth

GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines.
GSK

GSK receives EMA Orphan Drug Designation for GSK5764227 in Pulmonary NEC

GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK5764227 (GSK'227), has been granted Orphan Drug Designation by the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, including small-cell lung cancer.
GSK

GSK Plc gains FDA approval for Blenrep combination in multiple myeloma

GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies.
GSK Plc

GSK Plc names Luke Miels as CEO Designate, effective January 2026

GSK has announced the appointment of Luke Miels as CEO Designate, with full responsibilities and a Board position from 1 January 2026. Currently Chief Commercial Officer, Luke has been key in expanding GSK’s specialty medicines and vaccines portfolio, bringing senior experience from AstraZeneca, Roche and Sanofi-Aventis.
GSK

GSK’s Gepotidacin receives US FDA Priority Review for gonorrhoea treatment

GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over.

    Latest interviews

    View all interviews 

    Company Presentations

    View all Company Presentations

    BrokersTalk

    View all Broker Talk

    FTSE 100 News

    Search

    Search

    Green News

    View all Sustainable sectors, Plcs and news  

    Q&A's

    View all Question and Answers

    Funds

    View all Funds, Market Insights and news

    UK Broker Ratings

    Hardman & Co

    Don't Miss Our News Alerts

    Subscribe Free

    Find us on:

    Linkedin Facebook

    Follow us on Social Media:

    Home X-twitter Linkedin Facebook Spotify Apple